Radiation + Temozolomide for Glioblastoma
What You Need to Know Before You Apply
What is the purpose of this trial?
In this study we propose to determine outcomes of patients age 70 or older treated with radiation over 2 weeks given with temozolomide 75 mg/m2 daily during radiotherapy and as a post radiation treatment of 150 mg/m2 - 200 mg /m2 for 6 cycles or until the disease progresses.
Who Is on the Research Team?
Shiao Woo, MD
Principal Investigator
James Graham Brown Cancer Center
Are You a Good Fit for This Trial?
This trial is for patients over 70 with newly diagnosed glioblastoma who haven't had prior treatments. They must have a life expectancy of more than 6 months, good organ and marrow function, and be able to consent. Excluded are those with other cancers (unless low risk or certain types within the past 5 years), severe illnesses, or HIV on antiretrovirals.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Radiation
Participants receive hypofractionated radiotherapy with concurrent temozolomide
Adjuvant Treatment
Participants receive up to 6 cycles of adjuvant temozolomide treatment
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Hypofractionated radiotherapy
- Temozolomide
Hypofractionated radiotherapy is already approved in European Union, United States, Japan for the following indications:
- Esophageal adenocarcinoma
- Gastroesophageal junction adenocarcinoma
- Esophageal adenocarcinoma
- Gastroesophageal junction adenocarcinoma
- Esophageal squamous cell carcinoma
- Esophageal adenocarcinoma
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Louisville
Lead Sponsor
James Graham Brown Cancer Center
Collaborator